Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

Technology appraisal guidance
Reference number: TA218
Published: 23 March 2011

History

Background information

Review Decision - April 2014 information
Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 102 KB)

Published:

23 April 2014
Review Proposal - February 2014 information
TA218- Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia - Appendix A - provisional matrix of stakeholders (PDF 97 KB)

Published:

24 February 2014
TA218 - Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia - Appendix B - proposal paper presented to the Institute's Guidance Executive (PDF 257 KB)

Published:

24 February 2014
TA218 Myelodysplastic syndromes - azacitidine: press release information
2011/048 NICE recommends new treatment for myelodysplastic syndromes (PDF 73 KB)

Published:

06 December 2013

Myelodysplastic syndromes - azacitidine: equality impact assessment

Myelodysplastic syndromes - azacitidine: equality impact assessment (PDF 16 KB)

Published:

23 March 2011

Myelodysplastic syndromes - azacitidine: final appraisal determination 2

Myelodysplastic syndromes - azacitidine: final appraisal determination 2 information
Myelodysplastic syndromes - azacitidine: final appraisal determination (PDF 186 KB)

Published:

17 February 2011
Myelodysplastic syndromes - azacitidine: response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 89 KB)

Published:

17 February 2011
Myelodysplastic syndromes - azacitidine: consultee and commentator comments on the ACD
Myelodysplastic syndromes - azacitidine: Celgene (PDF 63 KB)

Published:

17 February 2011
Myelodysplastic syndromes - azacitidine: MDS UK Patient Support Group (PDF 269 KB)

Published:

17 February 2011
Myelodysplastic syndromes - azacitidine: Royal College of Nursing (PDF 59 KB)

Published:

17 February 2011
Myelodysplastic syndromes - azacitidine: Royal College of Pathologists and the British Society for Haematology (PDF 79 KB)

Published:

17 February 2011
Myelodysplastic syndromes - azacitidine: Royal College of Physicians on behalf of NCRI/RCP/RCR/ACP/JCCO (PDF 46 KB)

Published:

17 February 2011
Myelodysplastic syndromes - azacitidine: Department of Health (PDF 74 KB)

Published:

17 February 2011
Myelodysplastic syndromes - azacitidine: Decision Support Unit review of Celgene's response to the post appeal ACD (PDF 211 KB)

Published:

17 February 2011

Myelodysplastic syndromes - azacitidine: appraisal consultation

Myelodysplastic syndromes - azacitidine: appraisal consultation
Myelodysplastic syndromes - azacitidine: appraisal consultation document information
Myelodysplastic syndromes - azacitidine: additional information submitted by Celgene (PDF 478 KB)

Published:

01 November 2010
Myelodysplastic syndromes - azacitidine: critique of additional information by the Decision Support Unit (DSU)
Myelodysplastic syndromes - azacitidine: Decision Support Unit specification (PDF 64 KB)

Published:

04 November 2010
Myelodysplastic syndromes - azacitidine: report by the Decision Support Unit (PDF 132 KB)

Published:

04 November 2010
Myelodysplastic syndromes - azacitidine: addendum to the Decision Support Unit report (PDF 12 KB)

Published:

04 November 2010

Myelodysplastic syndromes - azacitidine: appeal decision

Myelodysplastic syndromes - azacitidine: appeal decision (PDF 73 KB)

Published:

26 July 2010

Myelodysplastic syndromes - azacitidine: appeal announcement

Myelodysplastic syndromes - azacitidine: appeal announcement information
Celgene Ltd
Appeals received (PDF 1.03 MB)

Published:

01 June 2010
Initial scrutiny letter (PDF 128 KB)

Published:

01 June 2010
Response to scrutiny letter
Celgene response to initial scrutiny letter (PDF 179 KB)

Published:

01 June 2010
Celgene appeal letter amended (PDF 373 KB)

Published:

01 June 2010
Final scrutiny letter (PDF 93 KB)

Published:

01 June 2010
Response to final scrutiny letter (PDF 147 KB)

Published:

01 June 2010
Response to Celgene's final letter (PDF 75 KB)

Published:

01 June 2010
Royal College of Pathologists and British Society of Haematology
Appeals received (PDF 85 KB)

Published:

01 June 2010
Initial scrutiny letter (PDF 85 KB)

Published:

01 June 2010
Response to scrutiny letter (PDF 68 KB)

Published:

01 June 2010
Final scrutiny letter (PDF 69 KB)

Published:

01 June 2010
MDS Patient Support Group, Leukaemia Society and Rare Cancer Forum
Appeals received (PDF 725 KB)

Published:

01 June 2010
Initial scrutiny letter (PDF 90 KB)

Published:

01 June 2010
Response to scrutiny letter (PDF 609 KB)

Published:

01 June 2010
Final scrutiny letter (PDF 76 KB)

Published:

01 June 2010
Response to final scrutiny letter (PDF 627 KB)

Published:

01 June 2010
Response to final letter (PDF 69 KB)

Published:

01 June 2010
Royal College of Physicians, Medical Oncology Joint Special Committee
Appeals received (PDF 123 KB)

Published:

01 June 2010
Initial scrutiny letter (PDF 84 KB)

Published:

01 June 2010
Response to scrutiny letter (PDF 121 KB)

Published:

01 June 2010
Final scrutiny letter (PDF 68 KB)

Published:

01 June 2010
Ground 3 - Human Rights appeal point
Appeal Panel's legal advisors document (PDF 125 KB)

Published:

01 June 2010
Celgene's response (PDF 120 KB)

Published:

01 June 2010
MDS UK's response (PDF 640 KB)

Published:

01 June 2010
Appraisal Committee observations (PDF 102 KB)

Published:

01 June 2010

Myelodysplastic syndromes - azacitidine: notice of appeal

Myelodysplastic syndromes - azacitidine: notice of appeal information

Myelodysplastic syndromes - azacitidine: final appraisal determination

Myelodysplastic syndromes - azacitidine: final appraisal determination information
Myelodysplastic syndromes - azacitidine: final appraisal determination (PDF 117 KB)

Published:

04 March 2010
Myelodysplastic syndromes - azacitidine: response to consultee, commentator and public comments on the ACD (PDF 151 KB)

Published:

04 March 2010
Myelodysplastic syndromes - azacitidine: consultee and commentator comments on the ACD
Celgene - ACD response (PDF 688 KB)

Published:

04 March 2010
Celgene - letter about Patient Access Scheme (PDF 32 KB)

Published:

04 March 2010
MDS UK Patient Support Group, Rarer Cancers Forum, Leukaemia CARE, Leukaemia Research Fund, Leukaemia Society and Macmillan Cancer Support (PDF 137 KB)

Published:

04 March 2010
Royal College of Nursing (PDF 6.9 KB)

Published:

04 March 2010
Royal College of Pathologists (RCPath) and the British Committee for Standards in Haematology (BCSH) (PDF 75 KB)

Published:

04 March 2010
Royal College of Physicians and Professor David Bowen on behalf of NCRI/RCP/RCR/ACP/JCCO) (PDF 19 KB)

Published:

04 March 2010
Department of Health (PDF 7.8 KB)

Published:

04 March 2010
Stockton PCT (PDF 118 KB)

Published:

04 March 2010
Welsh Assembly Government (PDF 7 KB)

Published:

04 March 2010
West London Cancer Network on behalf of Harrow PCT (PDF 17 KB)

Published:

04 March 2010
Harford (PDF 11 KB)

Published:

04 March 2010
Myelodysplastic syndromes - azacitidine: clarification request to Celgene, Celgene's response and ERG and DSU critique
Committee request to Celgene for clarification on their Appraisal Consultation Document response (PDF 36 KB)

Published:

04 March 2010
Further clarification request to Celgene (PDF 45 KB)

Published:

04 March 2010
Celgene's consolidated response to all clarification requests (PDF 268 KB)

Published:

04 March 2010
ERG critique of Celgene's response the Appraisal Consultation Document (PDF 484 KB)

Published:

04 March 2010
Addendum to ERG critique of Celgene's response to the Appraisal Consultation Document (PDF 44 KB)

Published:

04 March 2010
Decision Support Unit report (PDF 63 KB)

Published:

04 March 2010

Myelodysplastic syndromes - azacitidine: update to consultee and commentators

Myelodysplastic syndromes - azacitidine: update to consultee and commentators (PDF 10 KB)

Published:

08 October 2009

Myelodysplastic syndromes - azacitidine: appraisal consultation

Myelodysplastic syndromes - azacitidine: appraisal consultation
Myelodysplastic syndromes - azacitidine: appraisal consultation document information
Myelodysplastic syndromes - azacitidine: evaluation report
Pre-meeting briefing (PDF 277 KB)

Published:

03 August 2009
Evidence Review Group report (PDF 267 KB)

Published:

03 August 2009
Addendum Evidence Review Group Report (PDF 521 KB)

Published:

03 August 2009
Non-manufacturer submissions
Leukaemia Society (UK) and MDS Patient Support Group (PDF 51 KB)

Published:

03 August 2009
Rarer Cancers Forum (PDF 46 KB)

Published:

03 August 2009
Royal College of Nursing (PDF 12 KB)

Published:

03 August 2009
Royal College of Pathologists (PDF 39 KB)

Published:

03 August 2009
Royal College of Physicians (on behalf of National Cancer Research Institute/Royal College of Radiologists/Joint Collegiate Council for Oncology/Association of Cancer Physicians) (PDF 44 KB)

Published:

03 August 2009
Manufacturer submission
Manufacturer submission (PDF 2.02 MB)

Published:

03 August 2009
Appendix - Estimation of utilities for health states associated with different treatments for myelodyplastic syndrome (MDS) (PDF 446 KB)

Published:

03 August 2009
Expert written personal statements
Bowen (PDF 24 KB)

Published:

03 August 2009
Culligan (PDF 59 KB)

Published:

03 August 2009
Harford (PDF 17 KB)

Published:

03 August 2009
Pendleton (PDF 17 KB)

Published:

03 August 2009

Myelodysplastic syndromes - azacitidine: final matrix of consultees and commentators

Myelodysplastic syndromes - azacitidine: final matrix of consultees and commentators (PDF 33 KB)

Published:

29 January 2009

Myelodysplastic syndromes - azacitidine: final scope

Myelodysplastic syndromes - azacitidine: final scope (PDF 29 KB)

Published:

29 January 2009

Myelodysplastic syndromes - azacitidine: comments on the draft matrix

Myelodysplastic syndromes - azacitidine: comments on the draft matrix (PDF 21 KB)

Published:

29 January 2009

Myelodysplastic syndromes - azacitidine: draft matrix of consultees and commentators

Myelodysplastic syndromes - azacitidine: draft matrix of consultees and commentators (PDF 34 KB)

Published:

29 January 2009

Myelodysplastic syndromes - azacitidine: comments on the draft scope

Myelodysplastic syndromes - azacitidine: comments on the draft scope (PDF 130 KB)

Published:

29 January 2009

Myelodysplastic syndromes - azacitidine: draft scope

Myelodysplastic syndromes - azacitidine: draft scope (PDF 30 KB)

Published:

29 January 2009